Search Results for "activate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for activate. Results 561 to 570 of 1329 total matches.
Suvorexant (Belsomra) for Insomnia
The Medical Letter on Drugs and Therapeutics • Mar 02, 2015 (Issue 1463)
on suvorexant either continued on the active drug
or were switched to placebo for 2 months. Patients ...
The FDA has approved suvorexant (Belsomra –
Merck), the first orexin receptor antagonist to become
available in the US, for treatment of sleep-onset and/or
sleep-maintenance insomnia.
Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C
The Medical Letter on Drugs and Therapeutics • Aug 15, 2016 (Issue 1501)
. In vitro,
both sofosbuvir and velpatasvir have potent activity
against all major HCV genotypes (1-6 ...
The FDA has approved Epclusa (Gilead), a fixed-dose
combination of sofosbuvir (Sovaldi) and velpatasvir,
a new direct-acting antiviral agent, for oral treatment
of chronic hepatitis C virus (HCV) infection. Epclusa
is the first oral combination to be approved for
treatment of all six major HCV genotypes.
Cannabidiol (Epidiolex) for Epilepsy
The Medical Letter on Drugs and Therapeutics • Nov 05, 2018 (Issue 1559)
to an active metabolite
Elimination Primarily in feces
Half-life 56-61 hours
183
The Medical Letter ® Vol ...
The FDA has approved cannabidiol oral solution
(Epidiolex – Greenwich Biosciences) for treatment
of seizures associated with Dravet syndrome or
Lennox-Gastaut syndrome in patients ≥2 years old.
Cannabidiol (CBD) is a cannabinoid constituent of
the marijuana plant (Cannabis sativa). It is the first
natural marijuana product to be approved by the FDA
for any indication and the first drug to be approved in
the US for treatment of Dravet syndrome. Stiripentol
(Diacomit), which is not a marijuana product, was also
recently approved by the FDA for treatment of Dravet
syndrome in...
Stiripentol (Diacomit) for Dravet Syndrome (online only)
The Medical Letter on Drugs and Therapeutics • Mar 24, 2021 (Issue 1620)
of stiripentol increases serum concentrations of
clobazam and its active metabolite, which may
potentiate ...
The FDA has approved stiripentol (Diacomit – Biocodex)
for treatment of seizures in patients ≥2 years old with
Dravet syndrome who are also taking clobazam (Onfi).
Stiripentol, which has been available in Europe, Canada,
and Japan for many years, is the second drug to be
approved in the US for this indication; cannabidiol oral
solution (Epidiolex), a purified marijuana product, was
the first.
Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis (online only)
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
with methotrexate in patients with
active RA despite methotrexate therapy
Clinical improvement has occurred ...
View Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis
Dextromethorphan/Bupropion (Auvelity) for Depression
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022 (Issue 1666)
levorphanol; it does not have analgesic
activity. Its mechanism of action in treating MDD is
unknown ...
The FDA has approved an extended-release fixed-dose
combination of dextromethorphan and
bupropion (Auvelity – Axsome) for treatment of major
depressive disorder (MDD) in adults.
In Brief: Uridine Triacetate (Vistogard) for Fluorouracil Overdose
The Medical Letter on Drugs and Therapeutics • Jul 04, 2016 (Issue 1498)
activity of 5-fluorouridine triphosphate,
a fluorouracil metabolite, by competing ...
The FDA has approved the pyrimidine analog uridine triacetate (Vistogard – Wellstat Therapeutics) for emergency treatment of a fluorouracil (5-FU) or capecitabine (Xeloda, and generics) overdose or severe toxicity that occurs within 96 hours following administration of one of these drugs. Fluorouracil is a cytotoxic antimetabolite used to treat breast, colorectal, and other cancers; capecitabine is an oral prodrug of fluorouracil.Uridine triacetate, a prodrug, is deacetylated to uridine after oral administration. Excess circulating uridine is converted into uridine triphosphate, which...
In Brief: Femlyv – An Orally Disintegrating Hormonal Contraceptive
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024 (Issue 1717)
blister card
contains 24 active (0.02 mg of ethinyl estradiol and
1 mg of norethindrone acetate) and 4 ...
Femlyv (Millicent), an orally disintegrating tablet
containing ethinyl estradiol and norethindrone
acetate, has been approved by the FDA for prevention
of pregnancy in females with a body mass index (BMI)
≤35 kg/m2. It is the first hormonal contraceptive to
become available in an orally disintegrating tablet
formulation. Traditional oral and chewable tablets
containing ethinyl estradiol and norethindrone acetate
in a wide range of doses, including those found in
Femlyv, have been available in the US for years.
Med Lett Drugs Ther. 2024 Dec 9;66(1717):200 doi:10.58347/tml.2024.1717c | Show Introduction Hide Introduction
Drugs for HIV Infection
Treatment Guidelines from The Medical Letter • Feb 01, 2014 (Issue 138)
with documented resistance to
both PIs and other NNRTIs. Etravirine may be active
against some HIV-1 strains ...
Antiretroviral therapy is recommended for all HIV-infected
patients, both to reduce the risk of disease
progression and to prevent transmission of the virus to
others. Various guidelines for treatment of HIV infection
are available.
Topical Terbinafine for Tinea Infections
The Medical Letter on Drugs and Therapeutics • Aug 20, 1993 (Issue 903)
of ergosterol, an essential component of fungal cell membranes. Terbinafine is more active in vitro against ...
Terbinafine 1% cream (Lamisil - Sandoz), an allylamine synthetic antifungal drug chemically related to naftifine (Naftin - Medical Letter, 30:98, 1988), is now available in the USA for topical treatment of tinea pedis, tinea cruris, and tinea corporis infections. An oral formulation is available in Europe and is under investigation here.